Oppenheimer & Co’s TG Therapeutics TGTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.45M Sell
26,002
-12
-0% -$649 0.02% 759
2026
Q2
$1.43M Buy
+26,014
New +$1.06M 0.02% 775
2024
Q4
– Sell
-32,470
Closed -$759K – 1644
2024
Q3
$759K Buy
+32,470
New +$709K 0.01% 887
2021
Q3
– Sell
-5,400
Closed -$209K – 1572
2021
Q2
$209K Sell
5,400
-5,700
-51% -$224K ﹤0.01% 1406
2021
Q1
$535K Buy
+11,100
New +$533K 0.01% 938

Other funds holding TGTX

Oppenheimer & Co's TGTX Position: Q3 2026 in Review

Oppenheimer & Co reduced its TG Therapeutics (TGTX) stake by 0.05% in Q3 2026, selling an estimated $649 and leaving 26,002 shares worth $1.45M. The position accounts for 0.02% of the portfolio, ranked #759.

Oppenheimer & Co first reported a position in TGTX in Q1 2021 and has held it in 5 quarters since. 455 funds tracked by Wall St. Rank hold TGTX as of Q3 2026.

  • Oppenheimer & Co held 26,002 shares of TG Therapeutics worth $1.45M as of Q3 2026.
  • Oppenheimer & Co sold 12 TG Therapeutics shares in Q3 2026, an estimated $649.
  • TG Therapeutics made up 0.02% of Oppenheimer & Co's portfolio in Q3 2026, its #759 holding.
  • Oppenheimer & Co first reported a position in TG Therapeutics in Q1 2021 and has held it in 5 quarters since.
  • 455 funds tracked by Wall St. Rank held TG Therapeutics as of Q3 2026.

Based on Oppenheimer & Co's 13F filing for Q3 2026, filed 26 Oct 2026.